Gain Therapeutics, Inc.
GANX
$1.65
-$0.04-2.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.32M | 2.81M | 2.72M | 2.22M | 1.19M |
| Gross Profit | -2.32M | -2.81M | -2.72M | -2.22M | -1.19M |
| SG&A Expenses | 2.15M | 1.98M | 2.37M | 2.15M | 2.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.47M | 4.79M | 5.09M | 4.37M | 3.33M |
| Operating Income | -4.47M | -4.79M | -5.09M | -4.37M | -3.33M |
| Income Before Tax | -4.47M | -4.74M | -5.67M | -4.43M | -3.26M |
| Income Tax Expenses | 70.10K | 549.30K | 141.20K | 100.50K | 504.70K |
| Earnings from Continuing Operations | -4.54M | -5.28M | -5.81M | -4.53M | -3.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.54M | -5.28M | -5.81M | -4.53M | -3.77M |
| EBIT | -4.47M | -4.79M | -5.09M | -4.37M | -3.33M |
| EBITDA | -4.46M | -4.78M | -5.09M | -4.36M | -3.32M |
| EPS Basic | -0.12 | -0.15 | -0.19 | -0.16 | -0.14 |
| Normalized Basic EPS | -0.07 | -0.08 | -0.12 | -0.10 | -0.07 |
| EPS Diluted | -0.12 | -0.15 | -0.19 | -0.16 | -0.14 |
| Normalized Diluted EPS | -0.07 | -0.08 | -0.12 | -0.10 | -0.07 |
| Average Basic Shares Outstanding | 37.82M | 35.00M | 30.34M | 28.69M | 27.71M |
| Average Diluted Shares Outstanding | 37.82M | 35.00M | 30.34M | 28.69M | 27.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |